Halozyme Therapeutics Inc (HALO)
50.86
+0.59
(+1.17%)
USD |
NASDAQ |
Jun 20, 16:00
50.86
0.00 (0.00%)
After-Hours: 20:00
Halozyme Therapeutics Revenue (Annual): 829.25M for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 829.25M |
| December 31, 2022 | 660.12M |
| December 31, 2021 | 443.31M |
| December 31, 2020 | 267.59M |
| December 31, 2019 | 195.99M |
| December 31, 2018 | 151.86M |
| December 31, 2017 | 316.61M |
| December 31, 2016 | 146.69M |
| December 31, 2015 | 135.06M |
| December 31, 2014 | 75.33M |
| December 31, 2013 | 54.80M |
| December 31, 2012 | 42.32M |
| Date | Value |
|---|---|
| December 31, 2011 | 56.09M |
| December 31, 2010 | 13.62M |
| December 31, 2009 | 13.67M |
| December 31, 2008 | 8.764M |
| December 31, 2007 | 3.800M |
| December 31, 2006 | 0.9817M |
| December 31, 2005 | 0.1272M |
| December 31, 2004 | |
| December 31, 2003 | |
| December 31, 2002 | |
| December 31, 2001 | 0.0247M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
195.99M
Minimum
2019
829.25M
Maximum
2023
479.25M
Average
443.31M
Median
2021
Revenue (Annual) Benchmarks
| Novavax Inc | 556.38M |
| Denali Therapeutics Inc | 330.53M |
| Allogene Therapeutics Inc | 0.095M |
| AIM ImmunoTech Inc | 0.202M |
| Protalix BioTherapeutics Inc | 65.49M |